Skip to main content

Lung Cancer

FDA Approvals, Lung Cancer, Select Drug Profiles
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Read More
FDA Approvals, Lung Cancer, Select Drug Profiles
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Read More
Lung Cancer
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
Read More
Lung Cancer
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Read More
FDA Approvals, In the News, Lung Cancer, Select Drug Profiles
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Read More
Lung Cancer
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer See also Value-Based Care
Read More
Lung Cancer
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Read More
Lung Cancer, Select Drug Profiles, Payers' Guide
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Read More
Lung Cancer
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases
Read More
Lung Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Read More
Page 2 of 5
Results 11 - 20 of 44